Browse studies

Find your next paid study

499 recruiting studies matching your filters

Revamping Exercise Assessments in Child Health (Project REACH)

This study is a cooperative investigation funded by the NIH. The project is a collaboration among three major NIH Clinical Translational Science Awardees: 1) U…

Cystic FibrosisSickle Cell DiseaseSARS CoV 2 Infection

Estimated

~$10 – $6,250

University of California, IrvineNCT05359991

Host Response to Infection and Treatment in the Filarial Diseases of Humans

This study will evaluate and treat patients with filarial infections to explore in depth the immunology of the disease, including susceptibility to infection, …

FilariasisHelminthiasisParasitic Infection+2 more

Estimated

~$10 – $675

National Institute of Allergy and Infectious Diseases (NIAID)NCT00001230

Phase 3

A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® Plus Standard Medical Treatment Compared to Placebo Plus Standard Medical Treatment to Prevent Infections in Patients With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce…

HypogammaglobulinemiaBacterial InfectionsB-cell Chronic Lymphocytic Leukemia+2 more

Estimated

~$10 – $8,750

Grifols Therapeutics LLCNCT05645107

Natural History, Genetics, Phenotype, and Treatment of Mycobacterial Infections

This study will examine the symptoms, course of disease and treatment of non-tuberculous mycobacterial (NTM) infections, as well as the genetics involved in th…

Mycobacterium Infections

Estimated

~$10 – $675

National Institute of Allergy and Infectious Diseases (NIAID)NCT00018044

Phase 3

A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on…

Viral Lung Infection and Acute Respiratory Failure

Estimated

~$10 – $7,500

AstraZenecaNCT05624450

Modeling Host-Pathogen Interaction Using Lymphoid Organoids

Background: Staphylococcus aureus (S.aureus) are bacteria that can make people sick. Sometimes, an S. aureus infection can develop inside the spine; these inf…

Staphylococcal Infections

Estimated

~$10 – $675

National Institute of Allergy and Infectious Diseases (NIAID)NCT06479837

CSP #2038 - COVID-19 Pharmacotherapy Effectiveness in the VA Healthcare System (COPE-VA)

The purpose of this study is to comprehensively describe the temporal and geographic utilization of COVID-19 therapies used for mild to moderate disease during…

COVID-19, SARS-CoV-2 InfectionRSVInfluenza

Estimated

~$10 – $675

VA Office of Research and DevelopmentNCT06160128

Phase 1

NADPH Oxidase Correction in mRNA Transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)

Background: CGD is caused by a gene mutation. For people with CGD, their cells cannot kill germs well, so they can get frequent or life-threatening infections…

Chronic Granulomatous DiseaseInfection

Estimated

~$10 – $5,625

National Institute of Allergy and Infectious Diseases (NIAID)NCT05189925

Phase 1

A Phase 1/2, Randomized, Controlled, Observer-blind, Multicentre Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of GSK Biologicals' Investigational Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) Combination and Investigational hMPV Vaccines When Administered Intramuscularly According to a Single Dose Schedule in Younger Adults ≥18 to ≤49 Years and Older Adults Aged ≥60 to ≤80 Years

The aim of this study is to evaluate the safety, reactogenicity, and immune response of the different formulations of the investigational RSV/hMPV combination …

Respiratory Syncytial Virus Infections+Metapneumovirus

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT07628049

Phase 2

VALganciclovir vs. LETermovir for Primary Prevention of CMV in Moderate to High-Risk Heart Transplant Recipients (The VALET-CMV Study)

The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate t…

CMV ViremiaHeart Transplant InfectionHeart Transplant Failure and Rejection

Estimated

~$10 – $6,250

Columbia UniversityNCT07079735

Observational

Enhanced Telemedicine in Primary Care for ARTIs (Tele-PARTI) Study

Young children often receive antibiotics for pediatric acute respiratory tract infections (ARTIs) - common childhood diagnoses like ear infections, strep throa…

Acute Respiratory Tract InfectionEar InfectionThroat Infection+2 more

Estimated

~$10 – $6,250

University of PittsburghNCT07845526

Phase 2

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety, Tolerability, and Efficacy of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus Who Are at High Risk of Progression to Severe Disease

The main purpose of this study is to investigate the antiviral effect of S-337395 compared with placebo among nonhospitalized adult participants with high-risk…

Respiratory Syncytial Virus Infections

Estimated

~$10 – $7,500

ShionogiNCT07214571